Právní předpis byl sestaven k datu 28.01.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva xxxxxxxxxxxx věcí,
kterým xx xxxx a xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, že xxx 1. října 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx republiky x prezident republiky xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x platnost dne 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 a xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X xxx rok 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Xx.X., XX.X., x. r.
vrchní xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx xxxx Xxxxxxx zakázaných látek x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx a francouzštině. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx soutěži x xxxxxx obdobím začínajícím xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx xxxxxxxxx, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx xxxxx
Xx xxxxxxx, že xxxx xxxxx nebo metoda xx zakázána Xxx xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx v Kodexu.
Specifické x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „pro xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x výjimkou těch xxxxxxxxxx v Seznamu xxxxxxxxxx xxxxx x xxxxx dopingu. Žádná Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx x článku „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx xxxxx x xxxxx x metody, xxxxx Sportovec xxxxxxxxxxxxx xxxx nebo xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx výkonu.“
Návykové xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx látky, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx označovány xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x této třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx látka, na xxxxxx xx xxxxxxxxxx xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem pro xxxxxxx použití x xxxx (xxxx. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, syntetické drogy, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.
Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) |
|
|
• |
1-androsteron (3ɑ-hydroxy-5a-androst-1-en-17-on) |
• |
gestrinon |
|
|
• |
1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
|
• |
4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-hydroxy-17α-metylestra-4,9-dien-3-on) |
|
|
• |
17ɑ-methylepithiostanol (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-norpregna-4-en-17α-ol) |
• |
trenbolon (17β-hydroxyestr-4,9,11-trien-3-on) |
|
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.
X1.2. XXXXXXX ANABOLICKÉ XXXXX
Xxxx xxxx včetně:
Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], xxxxxxx a xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.
X2.1. ERYTROPOETINY (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Aktivační xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xenon.
S2.1.3 Xxxxxxxxxx GATA, např. X-11706.
X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx EPO (XXXX).
X2.2. XXXXXXXXX XXXXXXX X XXXXXX UVOLŇUJÍCÍ FAKTORY
S2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, mimo xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (LH),
• hormon xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) a jeho xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, leuprorelin, nafarelin x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin x xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, např. XXX-9604 x xXX 176–191.
X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x jeho analogy, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,
• xxxxxxxxxxx růstového xxxxxxx (XXX) a jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X MODULÁTORY XXXXXXXXX XXXXXXX
Xxxx jiné xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• hepatocytový xxxxxxx xxxxxx (XXX)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• růstový faktor xxxxxxxx z krevních xxxxxxxx (XXXX)
• thymosin-β4 x jeho deriváty, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (VEGF)
a xxxxx růstové xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• inhalační salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;
• xxxxxxxxx xxxxxxxxxx: maximálně 25 mikrogramů xx 24 hodin.
POZNÁMKA
Přítomnost xxxxxxxxxxx x moči x xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx xxxxxxxxxxx v množství xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx za Xxxxxxxxx laboratorní xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 xxxx Specifické xxxxx.
Xxxxx zařazené do xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx včetně:
|
• |
2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 trion (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx nebo xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- proteiny xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu) |
|||
|
• |
protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx
X4.4.3 meldonium
S4.4.4 xxxxxxxxxxxx
X5 DIURETIKA X XXXXXXXXX LÁTKY
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx jsou Specifické xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, včetně xxxxx optických xxxxxxx, xxxx. d- x x-, xxxx xxxxxxxx.
Xxxx xxxx včetně:
• Xxxxxxxxx, xxxx např.:
acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;
• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;
• Desmopresin;
• Xxxxxxxxxx;
x xxxxx látky x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x zubní xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Vzorku Sportovce xxxxxxxx xxxx případně Xxx Soutěži xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx v xxxxxxxx anestezii), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx navíc x xx, xxxxx xxx xxxx udělena na xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx metody x xxxx třídě xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx heterologní xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx náhražky xx xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx x xxxxxx xx xxxxxx porušit xxxxxxxxx x platnost Xxxxxx odebraných při Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, např. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, chirurgických xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.
M3. XXXXXX X BUNĚČNÝ XXXXXX
X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx analogů, které xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo exprese xxxx xxxxxxxxxx mechanismem. Xx xxxx xxxx xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx genů x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické látky x výjimkou xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x l-, xxxx xxxxxxxx.
Xxxxxxxxxxx zahrnují:
S6.A: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx uveden x xxxxx xxxxxx, xx Xxxxxxxxxxx látkou.
S6.B: SPECIFICKÁ XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA) |
• |
famprofazon |
• |
oktopamin |
||
|
• |
3-metylhexan-2-amin (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx a jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx a xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x této xxxxx: diamorfin (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. d- x l, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny zakázané xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Návykové látky x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x xxxxxx (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx
• xxxxxxxx a xxxxxxxxxx tetrahydrokanabionoly (THC)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• kanabidiol
S9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [včetně xxxxxxxxxx (např. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX SPORTECH
Všechny xxxxxxxx látky v xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.
• lukostřelba (XX)*
• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / U-rampa a xxxxxxxxx X-xxxxx / xxx air
• automobilový xxxxx (FIA)
• xxxxxxxx xxxxxx (XXXX)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx terč
• xxxxxxxx (xxxxxxx disciplíny) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx č. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je zakázaný xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx xxxxx xxx 150 xxxxxxxxxx v 1 ml.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx vyšší než 10 xxxxxxxxxx v 1 xx.
4) epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, nebo xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx předpis x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.
Znění xxxxxxxxxxxx právních norem xxxxxx právních předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx shora uvedeného xxxxxxxx xxxxxxxx